US2023086472A1PendingUtilityA1

Human serum albumin variants and uses thereof

Assignee: CSL LTDPriority: Oct 18, 2017Filed: Aug 30, 2022Published: Mar 23, 2023
Est. expiryOct 18, 2037(~11.2 yrs left)· nominal 20-yr term from priority
A61K 47/643C07K 2319/31A61K 38/385C07K 14/765A61K 38/00A61P 7/04A61K 38/37A61K 38/36A61K 38/4846
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A serum albumin variant, or functional fragment thereof, comprising, one or more amino acid substitutions selected from (i) glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at position (522); (ii) valine substituted for alanine at position (552); and (iii) alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position (572).

Claims

exact text as granted — not AI-modified
1 . A serum albumin variant, or functional fragment thereof, comprising one or more amino acid substitutions selected from the group consisting of:
 (i) an amino acid selected from the group consisting of glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at a position corresponding to amino acid 522 of SEQ ID NO: 1;   (ii) valine substituted for alanine at a position corresponding to amino acid 552 of SEQ ID NO: 1;   (iii) an amino acid selected from the group consisting of alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at a position corresponding to amino acid 572 of SEQ ID NO: 1; and   (iv) combinations thereof.   
     
     
         2 . The serum albumin variant, or functional fragment thereof, of  claim 1 , wherein the serum albumin variant, or functional fragment thereof, binds with increased affinity to FcRn compared to a serum albumin set forth in SEQ ID NO: 1 or wherein the serum albumin variant, or functional fragment thereof, has an increased serum half-life compared to a serum albumin set forth in SEQ ID NO: 1. 
     
     
         3 . The serum albumin variant, or functional fragment thereof, of  claim 2 , wherein the binding affinity is measured at acidic pH. 
     
     
         4 . The serum albumin variant, or functional fragment thereof, according to  claim 1 , comprising:
 (i) an amino acid selected from the group consisting of glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at a position corresponding to amino acid 522 of SEQ ID NO: 1, and valine substituted for alanine at position 552 of SEQ ID NO: 1; or   (ii) an amino acid selected from the group consisting of glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at a position corresponding to amino acid 522 of SEQ ID NO: 1, and an amino acid selected from the group consisting of alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position 572 of SEQ ID NO: 1; or   (iii) valine substituted for alanine at a position corresponding to amino acid 552 of SEQ ID NO: 1, and an amino acid selected from the group consisting of alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position 572 of SEQ ID NO: 1; or   (iv) an amino acid selected from the group consisting of glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at a position corresponding to amino acid 522 of SEQ ID NO: 1, valine substituted for alanine at position 552 of SEQ ID NO: 1, and an amino acid selected from the group consisting of alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position 572 of SEQ ID NO: 1.   
     
     
         5 . The serum albumin variant, or functional fragment thereof, according to  claim 1 , further comprising tyrosine substituted for lysine at a position corresponding to amino acid 573 of SEQ ID NO: 1. 
     
     
         6 . The serum albumin variant, or functional fragment thereof, according to  claim 1 , comprising:
 (i) leucine substituted for glutamine at a position corresponding to amino acid 522 of SEQ ID NO: 1; and/or   (ii) valine substituted for alanine at a position corresponding to amino acid 552 of SEQ ID NO: 1; and/or   (iii) arginine substituted for glycine at a position corresponding to amino acid 572 of SEQ ID NO: 1.   
     
     
         7 . The serum albumin variant, or functional fragment thereof, according to  claim 1 , comprising:
 (i) leucine substituted for glutamine at a position corresponding to amino acid 522 of SEQ ID NO: 1, and arginine substituted for glycine at a position corresponding to amino acid 572 of SEQ ID NO: 1; or   (ii) leucine substituted for glutamine at a position corresponding to amino acid 522 of SEQ ID NO: 1, and valine substituted for alanine at a position corresponding to amino acid 552 of SEQ ID NO: 1; or   (iii) valine substituted for alanine at a position corresponding to amino acid 552 of SEQ ID NO: 1, and arginine substituted for glycine at a position corresponding to amino acid 572 of SEQ ID NO: 1; or   (iv) leucine substituted for glutamine at a position corresponding to amino acid 522 of SEQ ID NO: 1, and tyrosine substituted for lysine at a position corresponding to amino acid 573 of SEQ ID NO: 1; or   (v) valine substituted for alanine at a position corresponding to amino acid 552 of SEQ ID NO: 1, and tyrosine substituted for lysine at a position corresponding to amino acid 573 of SEQ ID NO: 1; or   (vi) arginine substituted for glycine at a position corresponding to amino acid 572 of SEQ ID NO: 1, and tyrosine substituted for lysine at a position corresponding to amino acid 573 of SEQ ID NO: 1; or   (vii) leucine substituted for glutamine at a position corresponding to amino acid 522 of SEQ ID NO: 1, valine substituted for alanine at a position corresponding to amino acid 552 of SEQ ID NO: 1, and arginine substituted for glycine at a position corresponding to amino acid 572 of SEQ ID NO: 1; or   (viii) leucine substituted for glutamine at a position corresponding to amino acid 522 of SEQ ID NO: 1, valine substituted for alanine at a position corresponding to amino acid 552 of SEQ ID NO: 1, and tyrosine substituted for lysine at a position corresponding to amino acid 573 of SEQ ID NO: 1; or   (ix) leucine substituted for glutamine at a position corresponding to amino acid 522 of SEQ ID NO: 1, arginine substituted for glycine at a position corresponding to amino acid 572 of SEQ ID NO: 1, and tyrosine substituted for lysine at a position corresponding to amino acid 573 of SEQ ID NO: 1; or   (x) leucine substituted for glutamine at a position corresponding to amino acid 522 of SEQ ID NO: 1, valine substituted for alanine at position 552 of SEQ ID NO: 1, arginine substituted for glycine at a position corresponding to amino acid 572 of SEQ ID NO: 1, and tyrosine substituted for lysine at a position corresponding to amino acid 573 of SEQ ID NO: 1.

Join the waitlist — get patent alerts

Track US2023086472A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.